New approaches for temozolomide therapy: Use in newly diagnosed glioma

Roger Stupp*, Edward Newlands

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations


Temozolomide is a novel oral alkylating agent that has been approved for the treatment of patients with refractory malignant glioma. Treatment with temozolomide is now being explored in patients with newly diagnosed malignant glioma in several ongoing clinical trials, and alternative treatment schedules are being evaluated. A schedule of continuous daily treatment with temozolomide for 6 or 7 weeks has been developed and determined to be safe, effective, and well tolerated. When temozolomide was continuously given along with a standard course of radiation therapy for 6 or 7 weeks, followed by adjuvant treatment with temozolomide, promising preliminary results were seen in patients with malignant gliomas.

Original languageEnglish (US)
Pages (from-to)19-23
Number of pages5
JournalSeminars in Oncology
Issue number4 SUPPL. 13
StatePublished - 2001

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'New approaches for temozolomide therapy: Use in newly diagnosed glioma'. Together they form a unique fingerprint.

Cite this